Related Experiment Video
Updated: Jan 19, 2026
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy
Kellye C Kirkbride1, Gerard C Blobe
1Duke University Medical Center, Departments of Medicine and Pharmacology and Cancer Biology, Box 2631 DUMC, 221B MSRB Research Drive, Durham, NC 27710, USA.
Abstract:
Cancers have developed numerous mechanisms for escaping the immune response, either by successfully evading a fully functional immune system or by actively suppressing the immune system so that they are no longer recognised or effectively eliminated. Current evidence supports active cancer cell-mediated immunosuppression via the secretion of the potent immunosuppressive cytokine, transforming growth factor-beta (TGF-beta), as the most general and potent mechanism for human cancer cells to escape the immune system. Efforts to bypass TGF-beta-mediated immunosuppression thereby represent an attractive therapeutic strategy for the chemoprevention and treatment of human cancers, both by directly increasing the efficacy of immunosurveillance and by increasing the efficacy of current immunotherapy strategies. Current approaches are limited by their nonspecific effects on the TGF-beta signalling pathway, as TGF-beta pathways which specifically mediate immunosuppression have not yet been defined. Future efforts should be directed towards elucidating specific TGF-beta pathways so that these can be targeted for the chemoprevention and treatment of human cancers.
Insights
Cancer cells suppress the immune system using transforming growth factor-beta (TGF-beta). Targeting specific TGF-beta pathways offers a promising strategy for cancer immunotherapy and prevention.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Cancers employ diverse mechanisms to evade immune detection and elimination.
- Active immunosuppression by cancer cells, particularly via transforming growth factor-beta (TGF-beta), is a primary escape strategy.
- TGF-beta's potent immunosuppressive activity hinders immune surveillance and elimination of cancer cells.
Purpose of the Study:
- To highlight the critical role of TGF-beta in cancer immune evasion.
- To underscore the therapeutic potential of targeting TGF-beta-mediated immunosuppression.
- To identify the need for specific TGF-beta pathway targeting in cancer treatment.
Main Methods:
- Review of current evidence on cancer-immune evasion mechanisms.
- Analysis of TGF-beta's role as an immunosuppressive cytokine in cancer.
- Evaluation of existing therapeutic strategies targeting TGF-beta signaling.
Main Results:
- Transforming growth factor-beta (TGF-beta) is a key mediator of cancer cell-induced immunosuppression.
- Bypassing TGF-beta-mediated immunosuppression enhances immunosurveillance and immunotherapy efficacy.
- Current TGF-beta targeting approaches lack specificity, affecting essential pathways.
Conclusions:
- Targeting TGF-beta-mediated immunosuppression is a vital strategy for cancer chemoprevention and treatment.
- Elucidating specific immunosuppressive TGF-beta pathways is crucial for developing effective therapies.
- Future research should focus on identifying and targeting these specific pathways for enhanced cancer therapy.
Related Concept Videos
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
11:06Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System
09:18Spheroid Assay to Measure TGF-β-induced Invasion
01:16TGF - β Signaling Pathway
02:25An Assay for Analyzing Test β-Glucan as an Immunotherapy Strategy against Brain Cancer Cells
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...